Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Leveraging Site-Selective Conjugation to Enable New Modalities & Groundbreaking Dual Payload ADCs With Superior Characteristics & Activity

By | 8 June 2026

Introducing the CysTyr Platform and design parameters required for a successful dual payload asset
Demonstrating significantly superior activity for dual payload ADCs versus leading ADCs in CDX and PDX models
Outlining CysTyr superior manufacturing resulting in unprecedented product purity and homogeneity with tunable DAR
Unveiling first report on NHP toxicity trial for CATB-101 and significant improvements in therapeutic index versus leading ADCs